May 2008
M	T	W	T	F	S	S
« Apr		Jun »
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30

Medical Articles 5/31

Posted by rob on May 31, 2008 under Uncategorized | Be the First to Comment

Posted by rob on May 27, 2008 under Uncategorized | Be the First to Comment

Hybridization
biosensor using 2-nitroacridone as electrochemical indicator for
detection of short DNA species of Chronic Myelogenous Leukemia.

Successful
combination therapy with infusion of allogenetic bone marrow
mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute
myelogenous leukemia.

Acquired toxoplasmic retinitis in an immunosuppressed patient: diagnosis by transvitreal fine-needle aspiration biopsy.

Medical Articles 5/23

Posted by rob on May 23, 2008 under Uncategorized | Be the First to Comment

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

Acyclovir Bioavailability in Patients With Acute Myelogenous Leukemia Treated With Daunorubicin and Cytarabine.

Cutaneous granulocytic sarcoma in myelodysplastic syndrome.

Irreversible sensorineural hearing loss due to Imatinib.

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.

Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.

Medical Articles 5/22

Posted by rob on May 22, 2008 under Uncategorized | Be the First to Comment

Human
flt3 is expressed at the hematopoietic stem cell and the
granulocyte/macrophage progenitor stages to maintain cell survival.

Once
daily iv busulfan and fludarabine (iv Bu-Flu) compares favorably with
iv busulfan and cyclophosphamide (iv BuCy2) as pretransplant
conditioning therapy in AML/MDS.

Long-term
follow-up of allogeneic hematopoietic stem cell transplantation for de
novo acute myelogenous leukemia with a conditioning regimen of total
body irradiation and granulocyte colony-stimulating factor-combined
high-dose cytarabine.

HLA-haploidentical
bone marrow transplantation for hematologic malignancies using
nonmyeloablative conditioning and high-dose, posttransplantation
cyclophosphamide.

High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Individual physician practice variation in hematopoietic cell transplantation.

Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.

Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.

Imatinib
mesylate therapy in chronic myeloid leukemia patients in stable
complete cytogenic response after interferon-alpha results in a very
high complete molecular response rate.

Medical Articles 5/17

Posted by rob on May 17, 2008 under Uncategorized | Be the First to Comment

Phase
II Trial of Tipifarnib as Maintenance Therapy in First Complete
Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk
Features.

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.

Activated Ca2+/Calmodulin-Dependent Protein Kinase II{gamma} Is a Critical Regulator of Myeloid Leukemia Cell Proliferation.

Head and neck extramedullary disease as the initial presentation of acute myelogenous leukemia in a child.

Medical Articles 5/16

Posted by rob on May 16, 2008 under Uncategorized | Be the First to Comment

[Survival in adults with acute myelogenous leukemia.]

Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.

Phospho-STAT5
expression pattern with the MPL W515L mutation is similar to that seen
in chronic myeloproliferative disorders with JAK2 V617F.

[A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate]

Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.

Chronic leukocytosis.

CD8+
but not CD4+ T cells require cognate interactions with target tissues
to mediate GVHD across only minor H antigens, whereas both CD4+ and
CD8+ T cells require direct leukemic contact to mediate GVL.

Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis.

Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen-mismatched unrelated donors.

Medical Articles 5/14

Posted by rob on May 14, 2008 under Uncategorized | Be the First to Comment

Imatinib
resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss
of TP53 but without BCR/ABL kinase domain mutation in chronic
myelogenous leukemia.

Paracentric
inversion-associated t(8;21) variant in de novo acute myelogenous
leukemia: characteristic patterns of conventional cytogenetics, FISH,
and multicolor banding analysis.

A novel five-way chromosomal translocation observed in chronic myelogenous leukemia.

Review: recent clinical trials in epigenetic therapy.

Management of patients with resistant or refractory chronic myelogenous leukemia.

Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Imatinib
mesylate-related fatal acute hepatic failure in a patient with chronic
myeloid leukaemia and chronic hepatitis B infection.

Simultaneous
targeting of Aurora kinases and Bcr-Abl kinase by the small molecule
inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL
mutations including T315I.

Dup-697,
a specific COX-2 inhibitor, suppresses growth and induces apoptosis on
K562 leukemia cells by cell-cycle arrest and caspase-8 activation.

Medical Articles 5/12

Posted by rob on May 12, 2008 under Uncategorized | Be the First to Comment

Immunophenotypic study of basophils by multiparameter flow cytometry.

Omacetaxine
mepesuccinate – a semisynthetic formulation of the natural antitumoral
alkaloid homoharringtonine, for chronic myelocytic leukemia and other
myeloid malignancies.

Medical Articles 5/10

Posted by rob on May 10, 2008 under Uncategorized | Be the First to Comment

Immunophenotypic study of basophils by multiparameter flow cytometry.

Omacetaxine
mepesuccinate – a semisynthetic formulation of the natural antitumoral
alkaloid homoharringtonine, for chronic myelocytic leukemia and other
myeloid malignancies.

Medical Articles 5/9

Posted by rob on May 9, 2008 under Uncategorized | Be the First to Comment

[Mycobacterial
infection caused by Mycobacterium avium in allogenic bone marrow
transplant recipient with concomittant bronchiolitis obliterans as a
manifestation of graft versus host disease - case report and review of
the literature.]

Novel
chromosomal aberration in Philadelphia negative cells of a patient with
chronic myelogenous leukemia treated with dasatinib.

MPL W515L mutation in Chinese patients with myeloproliferative diseases.

Induction of NKG2D Ligands and Subsequent Enhancement of NK Cell-mediated Lysis of Cancer Cells by Arsenic Trioxide.

Selection of HLA-A2 Restricted CML28 Peptide by Artificial Antigen-presenting Cells.

Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.

Overcoming
imatinib resistance using Src inhibitor CGP76030, Abl inhibitor
nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562
variants with BCR-ABL gene amplification.

Medical Articles 5/8

Posted by rob on May 8, 2008 under Uncategorized | Be the First to Comment

BCR-ABL
messenger RNA levels continue to decline in patients with chronic phase
chronic myeloid leukemia treated with imatinib for more than 5 years
and approximately half of all first-line treated patients have stable
undetectable BCR-ABL using strict sensitivity criteria.

Medical Articles 5/6

Posted by rob on May 6, 2008 under Uncategorized | Be the First to Comment

Genomic
structure, alternative splicing and expression of TG-interacting
factor, in human myeloid leukemia blasts and cell lines.

The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.

Sequential
topoisomerase targeting and analysis of mechanisms of resistance to
topotecan in patients with acute myelogenous leukemia.

Expression of the TRAIL receptors in blood mononuclear cells in leukemia.

[Effect
of recombinant human interleukin 11 on the platelet after hematopoietic
stem cell transplantation in patients with leukemia]

Imatinib
and nilotinib induce apoptosis of chronic myeloid leukemia cells
through a Bim-dependant pathway modulated by cytokines.

Medical Articles 5/3

Posted by rob on May 3, 2008 under Uncategorized | Be the First to Comment

GATA1
is overexpressed in patients with essential thrombocythemia and
polycythemia vera but not in patients with primary myelofibrosis or
chronic myelogenous leukemia.

Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis.

A
Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel
Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or
Refractory Hematologic Malignancies.

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

Early and late hemopoietic precursor cells in patients with chronic myeloproliferative diseases.

Medical Articles 5/1

Posted by rob on May 1, 2008 under Uncategorized | Be the First to Comment

[Treatment of acute leukemias and chronic myeloid leukemias]

[Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes]

Philadelphia
chromosome-positive chronic myeloid leukemia with p190(BCR-ABL)
rearrangement, overexpression of the EVI1 gene, and extreme
thrombocytosis: a case report.

A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9)(p14;q34).

CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia.

Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.

Archives

Recent Posts

Meta